Skip to main content
← All verified funding
Tier AUS

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

National Institutes of Health

Sign in and complete your Funding Passport to see whether you qualify — a transparent, rule-based verdict, not a black box.

Sign In

About this opportunity

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Required documents

The official source lists no specific documents here — confirm requirements before applying.

Source & verification trail

First retrieved
November 20, 2026
Last verified
November 20, 2026
Content fingerprint
fd4a340e68554f8d…